For a second year in a row, Currax delivered greater than 50% year-over-year revenue growth for CONTRAVE®/MYSIMBA® in 2024. These outsized results were driven by increased patient demand, improved ...

Currax Pharmaceuticals LLC ("Currax"), a specialty Pharmaceutical company with over 25 products, including the number one branded oral weight loss medication CONTRAVE® (naltrexone HCl/bupropion ...

including the number one branded oral weight loss medication CONTRAVE ® (naltrexone HCl/bupropion HCl), today announces 2024 over-performance for revenue, demand and achievement of key ...

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, safety, drug interactions, dosage and administration, and place in therapy of atomoxetine in the treatment of attention-deficit ...

Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer TA61 27 May 2003 27 May 2003 Guidance on the use of drugs for early thrombolysis in the treatment of acute ...

David Coghill; Tobias Banaschewski; Alessandro Zuddas; Antonio Pelaz; Antonella Gagliano; Manfred Doepfner ...

Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy TA117 24 January 2007 24 January 2007 Methadone and buprenorphine ...

The HCL journey has been relentless, gratifying and marked with a series of achievements. Our unified efforts have catapulted the company from a garage start-up to a conglomerate whose businesses span ...